🟢 Oncolytics Biotech is trading 6% up in pre-market with no clear company-specific catalyst

Oncolytics Biotech is trading 5.97% up at $0.79, based on the provided pre-market quote; no clear September 14, 2026 company-specific catalyst was identified.

• The latest announcement, dated September 10, reported positive preclinical pelareorep results with a pan-RAS inhibitor.
• Shares subsequently declined through September 11.
• Broader markets were weaker pre-market, so the gain does not clearly align with global sentiment.